Fundraising FoxBain Capital Life Sciences — 2021 Investments
8 investments dated 2021 · listed companies and verified rows first · show all
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.
BiotechHealthtechWaltham, US
René Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)inKatarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)
Board seatAndrew Hack· per SEC Form D
Co-investorsBay City CapitalF-Prime CapitalM VenturesMRL Ventures FundRA CapitalRiverVest Venture Partners+9 more
Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset.
BiotechEmeryville, US
Warner Biddle(Chief Executive Officer)inBrian Kotzin(Director)Ian Clark(Director)Ryan Jones(Executive Officer)Karen Walker(Executive Officer)Peter Maag(Executive Officer, Director)in
Co-investorsVida VenturesWestlake Village BioPartnersGilead SciencesInsight PartnersKleiner PerkinsNorthpond Ventures+3 more
Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology.
BiotechMedical DevicesCambridge, US
Richard Malley(Director)inKamran Tavangar(Executive Officer)Steven Brugger(Executive Officer, Director)in
BoardRobert More(Director)Frances Heller(Director)George Siber(Director)
Board seatAndrew Hack· per SEC Form D
Co-investorsEcoR1 CapitalForesite CapitalViking GlobalBain CapitalRock Springs CapitalT. Rowe Price
Nuvalent is a biopharmaceutical company focused on structure-based drug discovery and the development of precision oncology therapies.
BiotechHealthtechMedical DevicesCambridge, US
Matthew Shair(Director)inHenry Pelish, PhD(Chief Scientific Officer)R. Porter James(Executive Officer, Director)inJames Porter, PhD(Chief Executive Officer)Alex Balcom(Chief Financial Officer)inChristopher Turner, MD(Chief Medical Officer)
Board seatAndrew Hack· per SEC Form D
Co-investorsAvoro Capital AdvisorsDeerfield Management CompanyViking GlobalWellington Management
Biopharmaceutical company discovering and developing novel biologics, protein, and peptide therapeutics.
BiotechSouth San Francisco, US
Trisha Millican(Director)James Topper(Director)Otello Stampacchia(Director)David Hirsch(Director)Volker Schellenberger(Executive Officer)James Brush(Director)
Co-investorsFrazier Life SciencesLongitude CapitalViking GlobalBlackRockCasdin CapitalFranklin Templeton+6 more
BiotechPhiladelphia, US
Philip R. Johnson, M.D.(Executive Officer, Director)inDora Mitchell(Executive Officer)Lori Forrest(Executive Officer)Leon Moulder, Jr.(Director)Benjamin Lund(Director)in
BoardTomas Kiselak(Director)
Co-investorsAgent CapitalDC Investment PartnersLongwood FundOUP (Osage University Partners)Pfizer Venture InvestmentsQuan Capital+3 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.